Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax + IL-2 in Metastatic Renal Cell Cancer
NCT00083941Phase 2Completed
- Sponsor
- Oxford BioMedica
- Start
- Aug 2004
- Primary completion
- Jul 2008
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MVA-5T4 in renal cell carcinoma (RCC), sponsored by Oxford BioMedica. Primary endpoints: Safety and tolerability of TroVax injections and Immune responses induced by treatment with TroVax. Started Aug 2004; status: completed.
02
Drugs
MVA-5T4
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00083941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083941.